David Segal, PhD

I have been an academic researcher in the Angelman field since 2007. I am developing two therapeutic approaches, and have been an author on 15 publications.

David Segal, PhD

Board Member

Professor

University of California, Davis

Specialties: Genomic therapeutics

Website

Email: djsegal@ucdavis.edu

David Segal received his Ph.D. from the University of Utah performed a post-doc at The Scripps Research Institute. Now at UC Davis, Dr. Segal’s research focuses on gene and epigenome editing to treat Angelman syndrome and related neurologic disorders. He is a founding member of the Interventional Genetics Program at the UC Davis MIND Institute, an investigator in the NIH Somatic Cell Genome Editing Consortium, and Editor-in-Chief of Frontiers in Genome Editing.

FAST Global Science Summit Presentations

Progress Toward ATF and CRISPR Therapies for Angelman Syndrome
Keynote address: Now Is the Time for Molecular Therapy

Notable Publications

Transcriptional Reprogramming Restores UBE3A Brain-Wide and Rescues Behavioral Phenotypes in an Angelman Syndrome Mouse Model.
UBE3A: An E3 Ubiquitin Ligase With Genome-Wide Impact in Neurodevelopmental Disease.
Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain.

For Researchers

For Pharma

For Families & Caregivers

For Donors & Investors

David Segal, PhD

Board Member

Professor

FAST Global Science Summit Presentations

Notable Publications